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Abstract 
Hepatitis C virus (HCV) infection is responsible for both hepatic and extra-hepatic disorders 
(HCV-EHDs); these latter are clearly correlated with HCV lymphotropism causing immune-
system dysregulation as well as with viral oncogenic potential. The spectrum of HCV-EHDs 
range from mild-moderate manifestations such as arthralgias, sicca syndrome, peripheral 
neuropathy, to severe, life-threatening complications, mainly vasculitic and neoplastic 
complications. Given the clinical heterogeneity of HCV-EHDs, HCV-infected individuals are 
frequently referred to different specialists according to the presenting/prevalent symptom(s); 
therefore, comprehensive diagnostic guidelines are necessary for a whole patient’s 
assessment that is decisive for early diagnosis and correct therapeutic approach of various 
hepatic and HCV-EHDs, regardless the specific competencies of single referral centers. 
In this respect, a multidisciplinary network of experts, the International Study Group of 
Extrahepatic Manifestations Related to Hepatitis C Virus Infection (ISG-EHCV), elaborated 
diagnostic guidelines of HCV-EHDs based on different proven expertises. 
There was a broad consensus among ISG-EHCV members on the proposed guidelines, taking 
into account two main levels of patients’ assessment. At the referral, all patients with HCV 
infection should be invariably examined by means of first-line diagnostic procedures including 
virological and hepatic parameter evaluation, as well as the detection of clinical findings 
suggestive of one or more HCV-EHDs. This preliminary assessment may reveal specific HCV-
EHDs, which will be deeper investigated by means of second-line, targeted investigations.  
The proposed multidisciplinary expert statement represents the first attempt to draw 
comprehensive diagnostic guidelines for HCV-infected individuals encompassing the entire 
spectrum of HCV-related disorders, namely typical hepatic manifestations along with less 
common, often unpredictable HCV-EHDs. These latter, alone or more often in combination 
with liver involvement, may unfavorably contribute to the overall disease outcome in a 
significant number of HCV-infected individuals.  
In conclusion, the application of standardized, thorough diagnostic guidelines is greatly 
advisable since the patient’s referral and during the follow-up; the proposed strategy is critical 
for the whole patient’s clinical outcome, as well as for etiopathogenetic studies needing 
homogeneous disease subsets. 
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1. Introduction 
 
Hepatitis C virus (HCV) infection represents one of the most challenging health problems 
considering its large diffusion worldwide and the frequent complication with both hepatic and 
extra-hepatic disorders (HCV-EHDs) (1-6). In term of morbidity and mortality HCV-infected 
individuals are at risk of the most harmful hepatic complications, i.e. cirrhosis and liver cancer  
(7), and less frequently of HCV-EHDs. These latter are the result of immune-system 
dysregulation due to the lymphotropism of HCV (1-3, 6, 8) responsible for different 
autoimmune and/or lymphoproliferative disorders that may severely affect the overall 
patients’ outcome (1-6, 9-11).  Single HCV-EHDs are characterized by widely variable 
distribution among patients’ populations from different countries (1-6); moreover, the 
percentage of patients with at least one HCV-EHDs may increase during the natural course of 
HCV infection (1-6, 10, 11). However, the actual incidence of HCV-EHDs is not systematically 
investigated worldwide, probably due to their insidious, often subclinical course, and mostly 
to the lack of uniform diagnostic approach to HCV-infected patients. As consequence, the 
overall incidence of HCV-EHDs can be underestimated or in some instances overlooked 
entirely. The present work is the first attempt to draw comprehensive diagnostic guidelines 
for patients with HCV-EHDs based on international, multidisciplinary expert consensus 
statement.  
 
1.1. Background 
HCV is both hepato- and lymphotropic virus (1-6, 8); these biological characteristics may 
explain the variety of HCV-related hepatic and extrahepatic disorders (1-6, 8). Following the 
discovery in 1989 of HCV as the major agent of non-A/non-B chronic hepatitis (12), mixed 
cryoglobulinemia syndrome (MCs) was the first well-recognized condition that may 
complicate long-lasting HCV infection (1-6, 13). MCs is a systemic, multifaceted condition 
mimicking various autoimmune-lymphoproliferative diseases; therefore, initial studies on 
HCV-related MCs prompted a number of clinico-epidemiological investigations regarding 
other disorders potentially triggered by the same causative agent. During the last decades an 
increasing number of clinical investigations on large cohorts of HCV chronically infected 
individuals focused on different putative HCV-EHDs (1-6, 14). Fig. 1 shows a provisional 
classification of HCV-EHDs according to the strength of association based on multiple clinico-
epidemiological, and laboratory parameters  (1-6); in particular, the prominent role of HCV in 
the large majority of patients with MCs and in a significant percentage of B-cell non-Hodgkin’s 
lymphomas (B-NHL). Both disorders can be regarded as direct consequence of HCV 
lymphotropism (1-6, 15, 16). The geographical disomogeneous distribution of HCV-EHDs 
suggests a multifactorial etiopathogenetic mechanism of HCV-EHDs, including environmental 
and/or predisposing genetic co-factors (1-6). In addition, HCV syndrome encompassing both 
hepatic and HCV-EHDs is the result of multistep pathogenetic process; the symptom 
composition may largely modify during the patients’ long-term follow-up (Fig. 2; 1,2,4,10). 
Therefore, a systematic clinical evaluation of possible hepatic and HCV-EHDs is essential for 
effective HCV-infected patients’ management, and not secondarily for valuable 
etiopathogenetic studies on homogeneous patients’ subsets.  
 
1.2. Methods 
The International Study Group of Extrahepatic Manifestations Related to Hepatitis C Virus 
Infection (ISG-EHCV) is a multidisciplinary network of experts formed in order to provide a 
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homogeneous diagnostic and therapeutic approach to patients with HCV-EHDs. With regards 
to the production of diagnostic guidelines the ISG-EHCV convenor and co-convenors invited 
other ISG-EHCV members on the basis of their well-known expertise in the field of HCV-
related manifestations. This task force initially gathered via e-mail and successively via 
teleconference meetings for the discussion of different issues; in addition, a systematic review 
of the literature was done in order to identify articles in English or in any language with 
English abstracts correlated to different topics of the study.  
When available, disease definitions and validated classification/diagnostic criteria, as well as 
standardized methodologies for serological investigations and single organ damage detection 
were followed (1-6, 14, 17, 18), including current classification criteria for well-definite 
disorders such as MCs, primary Sjögren's syndrome (pSS), rheumatoid arthritis (RA), and 
autoimmune hepatitis (17-23). 
 
 
1.3. Results. 
 
1.3.1. General patients’ assessment.  
In the clinical practice, it is widely demonstrated that different HCV-EHDs (Fig. 1, 2) may 
potentially develop at any time during the natural course of HCV infection (1-6, 10). 
Consequently, the ISG-EHCV recommends that all HCV-positive individuals should undergo a 
comprehensive clinical evaluation at the first visit (Tab. 1) and at regular time intervals during 
the follow-up for both liver involvement and HCV-EHDs. For a correct clinical monitoring and 
early detection of HCV-EHDs each patient should be provided with a booklet for symptom 
recording. 
The patient’s first evaluation is mainly based on a thorough questionnaire and physical 
examination able to identify different signs and symptoms of disease (Tab. 1); a core set of 
laboratory and instrumental investigations is also required in order to reveal the main HCV-
related organ- and/or non-organ-specific manifestations (Fig. 2, 3).  
Patients with clinical and/or laboratory alterations suggestive of one or more HCV-EHDs 
should be thoroughly evaluated by means of second-line, targeted clinical investigations (Tab. 
1) (Fig. 4). 
 
1.3.2. Diagnosis of single HCV-EHDs. 
Clinical characteristics and diagnostic guidelines of different HCV-EHDs are described in detail 
in the following paragraphs. 
 
 
Mixed cryoglobulinemia syndrome. 
 
MCs represents the most common and widely investigated condition among different HCV-
EHDs (1-6, 24, 25). The disease is generally classified as systemic vasculitis, in the setting of 
small-vessel vasculitides (1-6); therefore, the terms MCs and cryoglobulinemic  vasculitis are 
generally referred to the same clinico-pathological entity (1-6). Circulating mixed 
cryoglobulins represent the biological hallmark of MCs, which is characterized by typical 
clinical triad -purpura, weakness, and arthralgias-, low complement C4 fraction, cutaneous 
leucocytoclastic vasculitis, and multiple visceral organ involvement (1-6, Fig. 2). With the 
discovery of the causative role of HCV in the large majority of patients, the term ‘essential’ is 
referred to a low percentage of MCs patients (1-6, 13); the association with HCV infection is 
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particularly frequent in some geographical areas, such as Southern Europe, where the 
presence of other HCV-EHDs are rather observed (1-6). The HCV is directly involved in the 
pathogenesis of the disease through the virus-driven ‘benign’ B-cell lymphoproliferation, 
which is the pathological substrate of MCs (1-6), and the consequent production of circulating 
cryo- and non-cryoprecipitable immune complexes responsible for vasculitic manifestations 
(1-6).  
Diagnostic guidelines. Serum cryoglobulins are frequently detected in HCV-infected patients, 
often without relevant clinical significance (1-6, 24); only a minority of individuals may 
develop overt MCs, generally after a long-lasting HCV infection. The levels of serum mixed 
cryoglobulins may largely vary among patients and in the same patients during the natural 
course of the disease (10). Therefore, in subjects with suspected MCs the detection of serum 
mixed cryoglobulins may be temporarily negative; in these cases repeated laboratory 
examinations may be necessary to avoid false-negative determination (1, 4, 10). The MCs is 
characterized by variable symptom combination; it is not rare to observe in a single patient 
the entire spectrum of MCs symptoms during the natural course of disease: from mild 
manifestations, i.e. arthralgias, orthostatic purpura, to multiple organ involvement such as 
glomerulonephritis, hepatitis/cirrhosis, sensory-motor neuropathy, and/or B-NHL, generally as 
late disease complication (1, 10). This multifaceted syndrome may frequently overlap with 
other disorders making particularly difficult the diagnosis in individual patients (1-6, 9, 26). 
The differential diagnosis with other overlapping conditions, mainly pSS and RA, is shown in 
Tab. 2 (9, 26, 27). Preliminary classification criteria for MCs have been proposed by an 
international study group in 2011 and successively validated in a large MCs patients’ series 
showing a good sensitivity and specificity (17-18). Detection of serum mixed cryoglobulins is 
the prerequisite along with a combination of clinico-anamnestic symptoms and laboratory 
alterations. In all cases, other possible conditions, mainly infectious or neoplastic disorders, 
potentially associated with cryoglobulinemia must be excluded; among these the 
hematological malignancies that represent the most frequent causes of cryoglobulinemia, 
generally type I, monoclonal cryoglobulinemia (1-6). 
 
 
 
Arthritis. 
 
Patients with HCV infection and more frequently those with HCV-related MCs complain of 
arthralgias and less frequently of overt arthritis (1-6, 9, 25, 26, 28). This latter commonly 
appears as mono- oligoarthritis with non-erosive, scarcely aggressive joint involvement if 
compared with classical RA (9, 21). Patients with MCs may develop mild oligoarthritis, while 
RA-like polyarthritis may be sporadically observed in HCV-infected patients, either as distinct 
HCV-EHD or as self-limiting adverse affect of alpha-interferon treatment (9, 29). Considering 
the relatively high prevalence of both HCV infection and classical RA in the general population, 
it is possible to observe a simple disease association (9). Thus, differential diagnosis between 
HCV-related arthritis and classical RA is mandatory in patients with recent onset inflammatory 
joint involvement.       
Diagnostic guidelines. Tab. 2 reports the main clinico-radiological and serological parameters 
able to differentiate between arthritis complicating HCV infection and classical RA (9, 29). In 
particular, HCV-related arthritis is usually non-erosive and seronegative (absence of anti-cyclic 
citrullinated peptide antibodies) (see also Fig. 3, and 4). Overall, correct patient’s classification 
is essential for the therapeutic implications: mild-moderate HCV-related arthritis is commonly 
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responsive to conventional disease-modifying antirheumatic drugs (DMARDs), while patients 
with concomitant HCV infection and RA may be usefully treated with biological DMARDs; in 
particular, anti-TNFalpha antibodies are generally well tolerated despite the associated viral 
infection (30).  
 
 
Sicca syndrome. 
 
Sicca syndrome, i.e. xerosthomia and xeroftalmia, the clinical hallmark of pSS (19, 20), can be 
also observed in a variety of clinical conditions including HCV infection, as isolated 
manifestation or more frequently in association with HCV-related MCs (1-6, 28). Moreover, a 
role of HCV infection may be hypothesized in a small number of patients with SS (1-6, 31). 
Following available classification criteria for these conditions it is possible to correctly 
diagnose the majority of patients (17-20). In very few patients with concomitant HCV infection, 
MCs, and SS the differential diagnosis may be very difficult; thus, in the clinical practice it is 
more opportune to classify these patients as HCV-positive MCs/SS overlapping syndrome (9, 
19, 20, 31); they should be carefully monitored during the follow-up, considering the high risk 
of lymphomatous complications that characterize both diseases (1-3, 32-35).  
Diagnostic guidelines. On the basis of the above-mentioned diagnostic difficulties, a first line 
assessment of HCV-infected patients should include the routinely detection of sicca syndrome 
(Tab. 1). It can be successively classified as HCV-related sicca syndrome, alone or in the setting 
of MCs/SS (Tab. 2) according to current criteria by means of specific serological and 
instrumental investigations, namely serum mixed cryoglobulinemia, abnormally low 
complement C4, orthostatic purpura, anti-SSA/SSB antibodies with definite histopathological 
pattern of sialoadenitis of minor salivary glands (1-3, 17-20, 31-35).  
 
 
Porphyria cutanea tarda. 
 
The porphyrias are a clinically and genetically heterogeneous group of relatively rare 
metabolic disorders due to altered heme biosynthesis pathway (36). Porphyria cutanea tarda 
(PCT) represents the most common clinical variant of porphyrias; it can be categorized in two 
different subtypes: familial and sporadic (36). The disease is characterized by low activity of 
uroporphyrinogen decarboxylase (URO-D), the enzyme involved in the heme synthesis.
 
 In the 
familial variant, the enzyme defect is present in hepatocytes and other cells, such as 
erythrocytes; whereas in the sporadic PCT (more common) the URO-D activity is decreased to 
50%, affecting predominantly the hepatocytes. The URO-D deficiency is necessary but not 
sufficient for the clinical development of PCT, therefore possible pathogenetic co-factors have 
been proposed, including hepatotropic virus infection (1, 25, 36, 37). This latter hypothesis 
was also suggested by the frequent chronic liver involvement in patients with sporadic PCT 
(36). Since 1992, a pathogenetic role of HCV infection has been demonstrated in patients with 
sporadic PCT rather evident in some geographical area (38, 39, 40). The HCV-related PCT is 
particularly intriguing due to its pathogenetic implications (1, 25, 36-40). A direct role of HCV 
can be excluded considering the absence of altered porphyrine metabolism in HCV-positive 
patients without PCT; it is supposable a molecular mimicry phenomenon between 
predisposed host and HCV antigens, while altered genes connected with iron metabolism
 
may 
enhance the immune-reactivity of PCT patients (36-40).                                                                                                                                    
Diagnostic guidelines. In HCV-infected patients diagnosis of PCT can be adequately suggested 
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by typical cutaneous lesions, namely bullae, hyperpigmentation, and erosions at sun-exposed 
areas such as hands and face and definitely ascertained by means of simple laboratory 
investigations (Tab. 1, Fig. 3, 4). In particular, the presence of URO-D deficiency and elevated 
levels of serum and urinary porphyrins may confirm the diagnosis of PCT (36). Finally, it is 
opportune to complete the patient’s clinical work-up with the evaluation of liver involvement 
that is frequently associated with both HCV and PCT (36). 
 
B-cell non-Hodgkin lymphoma 
After the first reports of a high prevalence of HCV infection in patients with B-cell non-
Hodgkin’s lymphomas (B-NHL) (15, 41), during the last 20 years the association between HCV 
infection and B-cell NHL has been clearly established: in a meta-analysis of case-control 
studies the pooled relative risk of all NHL among HCV-positive subjects was 2.5 (42). The 
fraction of NHL attributable to HCV is highly heterogeneous by geographical region and may 
reach 10% in highly endemic areas (1, 2, 16, 43-45). Marginal zone lymphoma (MZL), 
lymphoplasmacytic lymphoma and diffuse large B-cell lymphoma (DLBCL) are the histotypes 
most frequently associated with HCV infection (44). Molecular mechanisms of HCV-associated 
NHL development are still poorly clarified. Three general mechanisms have been proposed for 
HCV-related lymphomagenesis: continuous stimulation of lymphocyte B-cell receptors by virus 
antigens, oncogenic effect mediated by intracellular viral proteins during replication of HCV in 
B-cells, and B-cell damage for mutation of tumor suppressor genes, caused by a transiently 
intracellular virus ("hit and run" theory) (16). A subset of HCV-positive DLBCL share molecular 
features with MZL like mutations affecting the NOCTH pathway (46).                                  
Diagnostic guidelines. In subjects with HCV infection, diagnosis of lymphoma must be 
suspected on the basis of clinical symptoms (Tab. 1; Fig. 3-4) and confirmed by histological 
examination of involved tissue (nodal and extranodal) and specific histotype must be defined 
according to WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues (47). 
Cytology and flow cytometry analysis are generally not sufficient to establish a definitive 
diagnosis of NHL; however, in absence of nodal and extranodal disease, a diagnosis of 
monoclonal B-cell lymphocytosis (MBL) can be achieved in HCV-positive subjects with bone 
marrow histology coupled with flow cytometry findings in peripheral blood and bone marrow 
(48, 49). Also in specific situations as in splenic marginal zone lymphoma (SMZL), a reliable 
diagnosis can be assessed with bone marrow histology and phenotype evaluated by 
immunohistochemistry and flow cytometry without need of splenectomy 50). Overlapping 
histological features between HCV-positive and HCV-negative cases have been reported (49) 
but differential diagnosis between MBL and SMZL can be difficult in cases with a splenomegaly 
justified by HCV infection (35).                                                                                                        
Staging of HCV-associated NHL is to be performed according to Lugano classification (51), 
MZLs are generally not (FDG)-avid diseases and must be staged by means of computed 
tomography only; positron emission tomography (PET) is indicated in DLCBL and in indolent 
NHL in case of suspected transformation (52; Fig. 4).                                                                            
Specific clinical pictures of lymphomas associated with HCV infection have been reported. 
Among MZLs SMZL is frequently reported in association with HCV infection but there is a great 
geographic variability with significant HCV-subsets in some studies (43, 53) and rare cases in 
others (54). French authors described a form of SMZL associated with HCV infection and type 
II mixed cryoglobulinemia that affects mostly female subjects; symptomatic cryoglobulinemia 
iris-AperTO 
University of Turin’s Institutional Research Information System and Open Access Institutional 
Repository 
 
was present in the majority of patients (55). Also extranodal marginal zone lymphomas of 
MALT lymphomas are frequently associated with HCV infection (45); peculiar sites are 
reported like liver, salivary glands and ocular adnexa (32, 35, 56, 57, 58). A particular 
presentation of HCV-associated MALT lymphoma is the subcutaneous ‘lipoma-like’ MZL: this 
lymphoma has been described in old women presenting single or multiple soft and mobile 
subcutaneous nodules. The diagnosis can be postponed for many years for the benign 
appearance of the lesions and clinical course is usually indolent (59). In some cases MZL 
appear disseminated in HCV-positive patients and a specific MZL subtype is not identifiable 
(49). As outlined by epidemiological studies, also aggressive NHL can be HCV-related; in 
particular, a subset of apparently de novo diffuse large B-cell lymphoma emerged as a 
separate entity associated with HCV infection. HCV-positive DLBCL commonly present with 
advanced stage, extranodal localizations like spleen and liver and elevated levels of serum 
lactate dehydrogenase, that can be related also to the concomitant hepatitis (60-63). 
Recently, a new “HCV Prognostic Score” based on performance status, albumin and HCV-RNA 
load has been proposed as a specific prognostic tool for HCV-associated DLBCL. Further 
studies also suggest that HCV-associated DLBCL arises more frequently from a preceding low-
grade MZL in comparison to de novo DLBCL (46, 60, 62) and therefore pathologist should be 
aware of reporting a possible residual part of indolent NHL in the diagnostic sample. 
 
Kidney  
 
Nephropathy may develop in small percentage of HCV infected persons, with significantly 
higher frequency in patients with overt MCs (1-6, 10, 64). The predisposing factors include 
older age, longer duration of hepatitis, and genetic background (64).   
The prevalence of kidney involvement tends to increase during long-term follow-up, and 
glomerulonephritis may severely affect the overall prognosis of HCV-infected individuals.    
Cryoglobulinemic nephritis. The pathogenesis of HCV-related cryoglobulinemic nephritis is 
the ultimate result of poly-monoclonal expansion of B cells triggered by HCV through a 
sequence of  immunological alterations, i.e. chronic stimulation by HCV infection sustaining 
the synthesis of IgM rheumatoid factor and consequently of cryoprecipitable ICs, abnormal 
kinetics and tissue deposition of the HCV-containing ICs, and ineffective cryoglobulin 
clearance by monocyte/macrophages, which are implicated in perpetuating glomerular 
damage (65-71). 
Clinically, cryoglobulinemic glomerulonephritis may appear with one or more renal symptoms; 
namely, isolated proteinuria (<3 g/24 h), usually with microscopic hematuria (30%), nephrotic 
syndrome (20%), acute nephritic syndrome (15%) (some   patients show a mixed nephrotic 
and nephritic syndrome), macroscopic hematuria (10%), chronic renal insufficiency  (10%), 
acute renal failure (10%), and/or oligoanuria (5%) (64). 
Diagnostic guidelines are mainly based on renal biopsy that is mandatory in any patient with 
urinary abnormalities and/or unexplained renal impairment. Ultrasound kidney examination 
of patients with glomerulonephritis often reveals bilateral cortical hyperechogenicity, while 
urinary sediment shows a prevalence of polymorphic erythrocytes. However, quality and 
entity of histologic features, which affect the therapeutic approach, are unpredictable and 
required careful examination of renal specimens.  
Three main glomerular patterns can be recognized as a result of cryoglobulin glomerular 
deposition (64): a) diffuse membranoproliferative glomerulonephritis that is observed in about 
80 % of case,  
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b) focal membranoproliferative glomerulonephritis (about 10%)  
c) mesangial proliferative glomerulonephritis (10%)  
Interstitial and Vascular Lesions may include interstitial leukocyte infiltration and fibrosis 
usually focal and almost invariably associated with the membranoproliferative forms. 
Moreover, arteriolosclerotic lesions are present in one third of cases, while frank arteritis is 
rare. 
At immunofluorescence examination diffuse, pseudolinear peripheral capillary wall and 
mesangial staining for IgM, IgG, and C3 are usually found with a relatively stronger staining for 
IgMk compared to lambda light chain. Prominent IgM and IgG staining is detected in thrombi, 
while fibrinogen is found in vessel walls when vasculitis is present. Moreover, electron-dense 
deposits (electromicroscopy) are detected in subendothelial and mesangial areas together 
with interposition of glomerular basement membrane by monocytes. Cryoglobulin deposits 
often display short, curved, thick-walled tubular structures with a diameter of about 30 nm. 
Atypical features can be observed in few cases of membranoproliferative glomerulonephritis 
showing IgA with prevalent mesangial but also parietal localization. In very low percentage of 
patients, a pattern of membranous nephropathy can be detected with prevalent subepithelial 
deposits of IgM, IgG, and C3 with crystalloid structured deposits at the electron microscopy 
examination.   
The patients with diffuse membranoproliferative glomerulonephritis show a more remarkable 
C4 hypocomplementemia, higher levels of proteinuria and a stronger association with 
serositis, hepatosplenomegaly, leukopenia, peripheral neuropathy, and cardiac involvement 
compared to patients with other patterns. 
Significant prognostic variables include age, male gender, creatinine and proteinuria at the 
time of renal biopsy, number of clinical relapses, and poor blood pressure control.   
HCV-associated non-cryoglobulinemic glomerulonephritis. Due to the diverse histologic 
patterns and the specific therapeutic implications, biopsy should be done, if not specifically 
contraindicated, in every HCV infected patient who presents with urinary abnormalities or 
otherwise unexplained renal insufficiency. A number of alternative renal manifestations, 
beside cryoglobulinemic nephritis, can be found, including membranous nephropathy, focal 
segmental sclerosis, IgA nephropathy and other proliferative glomerulonephritis, non-
cryoglobulinemic membranoproliferative glomerulonephritis, fibrillary and immunotactoid 
glomerulopathies, and anti-cardiolipin-associated thrombotic microangiopathy (71). These all 
are conditions in which the electron microscopy evaluation is mandatory. 
It is not rare that membranoproliferative glomerulonephritis is one of presenting symptoms of 
HCV-associated MCs, while the overt cryoglobulinemic syndrome can appear as late 
manifestation (10). Therefore, HCV-positive patients with apparently isolated GN should 
undergo to careful clinico-serological assessment and follow-up in order to exclude other 
hepatic and extrahepatic disorders, especially the MCs. 
 
Endocrine disorders  
The most frequent endocrinological diseases in the setting of HCV-EHDs are autoimmune 
thyroid disorders (AITD) (72-77) and type 2 diabetes mellitus (T2DM) (78-85); moreover, an 
increased prevalence of gonadal dysfunction is reported in male HCV-infected individuals (86-
89). 
Thyroid disorders. A higher prevalence of thyroid disorders in patients with HCV-associated 
MCs, not only with respect to controls, but also to HCV patients without cryoglobulinemia was 
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shown, needing a careful monitoring of thyroid function in these patients (72-74). 
Furthermore, IFN-α therapy is a well-known risk for the development of AITD and 
dysfunctions (73). 
The presence of higher risk of AT and hypothyroidism, and increased circulating AbTPO levels, 
in female gender, characterized the pattern of thyroid disorders observed in MCs, similarly to 
HCV patients without MCs (75). Interestingly, the prevalence of papillary thyroid cancer has 
been found higher in chronically infected patients than in controls, as in HCV-related MCs 
patients, particularly in those with AT (73, 76, 77).  
Diagnostic guidelines. These findings suggest a careful monitoring of thyroid function and 
nodules in patients with risk factors (female gender, border line high initial TSH, AbTPO 
positivity, hypoechoic and small thyroid) for the development of thyroid autoimmunity in 
HCV-positive patients, with/without MCs (Tab. 1; Fig. 3-4). These patients should undergo to 
determination of free thyroxine (FT4), TSH, AbTg, AbTPO and thyroid ultrasonography 
approximately every year. In patients with thyroid nodules, a fine-needle aspiration should be 
performed, if larger than 1 cm, or in presence of suspected malignancy (Tab. 1; Fig. 3-4). 
 
Diabetes, and metabolic disturbances. Liver plays an important role in the carbohydrate 
metabolism, thus liver diseases, as chronic hepatitis and cirrhosis, are known to have a higher 
prevalence of disturbed glucose homeostasis, impaired glucose tolerance or insulin resistance 
(IR) (78, 79), eventually they can develop overt DM (80). 
Several epidemiological studies on the seroprevalence of HCV in diabetic patients have 
evidenced higher percentages than in controls, while analysis in patients seropositive for HCV 
without cirrhosis, or with MCs, showed higher prevalence of DM compared to HCV-negative 
controls or HBV-infected patients (81-83).  
Actually, how HCV leads to diabetes is still a matter for debate. The type of diabetes 
manifested by HCV-infected patients is not the classical T2DM: patients with HCV-associated 
T2DM were leaner than T2DM controls, and showed significantly lower low density 
lipoproteine (LDL)-cholesterol, systolic and diastolic blood pressure (82, 83). Furthermore, 
patients with HCV-related MCs and T2DM had non-organ-specific-autoantibodies more 
frequently (34% vs 18%) than non-diabetic HCV-related MCs patients (82). An immune-
mediated mechanism has been postulated for diabetes in HCV-infected patients with/without 
MCs (82). Moreover, clinical trials on HCV patients report improvement of glucose metabolism 
after antiviral treatment (84) suggesting a direct role of HCV in beta-cell dysfunction. 
In HCV patients the DM itself seems to have a selective impact on hepatocellular carcinoma 
development (HCC) (85), as well an increased risk to develop renal complications (90).         
Diagnostic guidelines. Consequently, a periodic evaluation of glycemia, HbA1c, and lipids in 
HCV patients is recommended (Tab. 1; Fig. 3).         
                                                                                                                                                                 
Gonadal dysfunction. Abnormal serum levels of sex hormones can be observed in HCV-
related MCs patients (86), while erectile dysfunction has been reported in some HCV-infected 
males during interferon-alpha treatment (87, 88). Considering anecdotal clinical observations, 
the prevalence of gonadal dysfunction has been evaluated in 207 HCV-infected male patients 
(102 with MCs) compared with 207 age- and sex-matched individuals, after the exclusion of 
patients aged over 55 years, recent interferon-alpha treatment, presence of renal failure, 
cardio-vascular and psychiatric disorders, diabetes, and/or hypothyroidism  (89). HCV-positive 
patients showed a higher prevalence of erectile dysfunction compared to controls (P < 0.001). 
In addition, abnormally low plasma levels of testosterone were detected in HCV-infected 
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individuals with erectile dysfunction. This latter was independent of the severity of hepatic 
damage.  
Diagnostic guidelines. As part of a comprehensive diagnostic approach it is advisable that 
male patients with HCV infection could be also evaluated for possible erectile dysfunction and 
hormonal status (Tab. 1; Fig. 3). When necessary, the correction of hormonal deficiency may 
improve the patient's quality of life; in addition, it may restore the inhibitory activity of 
androgens on the HCV-related immune-system alterations. 
 
 
Neurological and psychiatric disorders.                                                                                           
   The involvement of peripheral and/or central nervous system (CNS) represents one of the 
most frequent HCV-EHDs (91-97); the complex pathogenesis may include different 
mechanisms such as the direct HCV neuroinvasion,  the immune-mediated injury due to 
autoantibodies against nervous tissue autoantigens, the ischemic alterations secondary to 
either cryo- and non-cryoprecipitable immune-complex-mediated vasculitis or atherosclerotic 
vasculopathy (91-100). Up to 50% of HCV-infected patients may develop a variable 
combination of different subclinical or clinical manifestations: a) peripheral sensory, motor or 
sensorimotor mono-/polyneuropathies, small fiber sensory polyneuropathy (less frequently 
large fiber sensory neuropathy), and autonomic neuropathy; b) CNS manifestations including 
primarily immune-mediated nervous tissue injury (encephalopathy syndromes, myelitis, 
encephalomyelitis) and/or cerebrovascular events; these latter as consequence of vasculitic or 
vasculopathic ischemic damage; c) neuropsychological/-psychiatric manifestations; d) 
iatrogenic neurologic manifestations, mainly triggered by alpha-interferon treatment (101-
103).                                                                                                                                                        
Some important co-factor may contribute to neurological manifestations (long-lasting HCV 
infection, serum cryoglobulins, mainly clinically overt MCs, concomitant 
cardiovascular/metabolic disorders) together with some risk factors such as male gender, 
smoking, and/or other infectious diseases (93-95).                                                                                                        
Diagnostic guidelines. The clinical onset of peripheral neuropathy is often subacute with 
distal, symmetric, sensory or sensorimotor polyneuropathy, and less frequently as 
asymmetrical sensory/motor impairment. The most common symptoms are the sensory loss, 
paresthesias, numbness, cramps, burning feet, and tingling (91-97) (Tab. 1; Fig. 3-4). In a 
minority of cases the peripheral neuropathy may be complicated by severe sensory-motor 
manifestations, which may appear abruptly, often as asymmetric mononeuritis.  HCV-
associated restless legs syndrome has also been reported as expression of small fiber sensory 
polyneuropathy (94, 104, 105). All patients with suspected peripheral nerve involvement 
should be investigated by means of electromyography with peripheral nerve 
neurophysiological tests and when opportune by histological peripheral nerve examination 
(mainly sural), including the intraepidermal nerve fiber density  (105) (Tab. 1; Fig. 3-4).                                     
The CNS involvement is less frequently reported (92-95, 97); well-documented observations of 
HCV-associated vasculitic involvement of CNS are quite rare and include mostly cryoglobulin-
positive patients (94). Clinically, the CNS involvement may present with different symptoms, 
such as fatigue, depression, cognitive impairment, stroke episodes, transient ischemic attacks, 
progressive reversible ischemic neurological deficits, lacunar infarctions, or encephalopathic 
syndrome, which are generally attributable to ischemic events (vasculitic/vasculopathic) and 
only exceptionally to hemorrhage (92-95, 97). Patients with suspected or overt CNS 
involvement should be carefully evaluated by means of detailed neurological examination, 
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disease duration, previous/ongoing treatment (interferons), laboratory (serum cryoglobulins, 
monoclonal component), and instrumental investigations (Tab. 1; Fig. 3-4). In particular, the 
detection of CNS vasculitic/vasculopatic alterations may include: transcranial color-Doppler 
ultrasonography and magnetic resonance (MR) imaging; this latter plays an important role in 
the workup of patients with suspected vasculitis, even though the abnormalities found on MR 
imaging are not diagnostic. Brain MR includes a variety of methodologies able to evidence 
specific CNS alterations. Computed tomography (CT) is less sensitive than MR imaging in the 
assessment of cerebral vasculitis, with the exception of large ischemic infarctions and 
hemorrhage. Functional brain MR imaging studies could be usefully employed for specific CNS 
manifestations, as well as 18F-fluoro-deoxyglucose positron emission tomography scan. CT 
presents limited spatial resolution; however, it can show parenchymal brain calcifications 
found within old ischemic lesions (92-95, 97, 106, 107). CT angiography can be used to 
evaluate both vessel walls and lumen, and thus it may show vessel wall alterations when the 
lumen is still unaffected at conventional catheter angiography (106). Neuropsychiatric 
disorders and neurocognitive dysfunction are reported in nearly 50% of patients with chronic 
HCV infection, which are independent of the presence/severity of hepatic involvement, HCV 
genotype and/or viral load (95). Fatigue, sleep disturbance, depression and reduced quality of 
life are commonly associated with neurocognitive alterations in patients with non-cirrhotic 
HCV infection (95). These subjects should be evaluated for possible neurocognitive decline 
over time, including the evaluation of motor activity with sleep-wake-rhythm, question naires 
for depression and health-related quality of life (108).                                             
        Finally, patients with chronic HCV infection often have 
experience of unfavorable psychological conditions because of low socioeconomic status, 
concomitance of other infections, such as HBV or HIV, discrimination, and limited access to 
adequate health care (109). An accurate environmental and individual psychological 
assessment of these patients is mandatory for comprehensive counseling approach and 
management of the overall HCV syndrome (109). 
 
Cardiovascular                                                                                                                                   
An increased risk to develop cardiovascular diseases in patient with chronic HCV infection has 
been reported (110, 111). An independent risk factor for the development of some harmful 
cardiovascular manifestations such as carotid atherosclerosis, heart failure and above-
mentioned stroke has been more recently observed (110, 111, 112). More recently a number 
of data underlined an excess of cardiovascular mortality during the course of chronic HCV 
infection (113, 114). It is well-known that atherosclerosis is a chronic inflammatory disease 
secondary to multifactorial pathogenetic process; its incidence is significantly higher in 
patients with autoimmune and/or infectious diseases (115, 116). Thus, chronic HCV infection 
can be reasonably identified as a potential atherogenic condition considering the complex of 
HCV-driven autoimmune/inflammatory alterations, characterized by increased levels of pro-
atherogenic chemokines and cytokines
 
(74, 117) (Fig. 1-2). On the other hand, HCV may be 
considered a ‘metabolic’ virus, in particular it can promote insulin resistance and type 2 
diabetes, two leading pro-atherogenic conditions   (80, 83). Finally, HCV may direct promote 
atherosclerotic lesions as suggested by HCV detection and replication within carotid plaques 
(118). Clinical trials with antiviral treatments should indirectly clarify the actual atherogenic 
role of HCV infection in the near future.                                                                                             
Diagnostic guidelines. Considering the increased prevalence and prognostic relevance of 
cardiovascular events, it is clearly opportune to include these harmful manifestations among 
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HCV-EHDs. Therefore, a noninvasive screening (Tab. 1; Fig. 3-4) for cardiovascular alterations 
(Doppler ultrasound studies, EKG) is recommendable at the first patient’s assessment 
followed by careful monitoring during the follow-up.  
 
 
Miscellanea. 
A number of disorders has been suggested as possible HCV-EHDs on the basis of 
epidemiological studies, often referred to limited patients series, or simple anecdotal 
observations (Fig. 1, columns 3 and 4). In particular, various cutaneous manifestations might 
be correlated with HCV infection (37, 119), mainly the skin vasculitic lesions varying from 
orthostatic purpura, the cutaneous hallmark of MCs, to severe necrotizing lesions (1-6). Other 
cutaneous symptoms such as pruritus, chronic urticaria, or psoriasis have been also associated 
to HCV infection (37, 119, 120, 121). Furthermore, an heterogeneous assortment of diseases, 
namely lichen planus, Mooren corneal ulcer, osteosclerosis, fibromyalgia, lung alveolitis, 
autoimmune hepatitis, poly-dermatomyositis, and panarteritis nodosa have been correlated 
to HCV infection, generally with a low strength of association (1-6, 9, 37, 119, 122-128) (Fig. 1).  
For each condition the actual causative role of HCV remains still to be definitely ascertained; 
among these, subclinical lymphocytic alveolitis has been detected in a significantly percentage 
of HCV-positive patients series, which in rare cases may lead to severe lung fibrosis (1, 123). 
This intriguing association might represent a model of virus-driven interstitial lung 
involvement; on the other hand, it suggests the opportunity of including HCV detection in the 
clinico-laboratory work-up of patients with apparently idiopathic lung fibrosis (129). 
Comparable diagnostic approach is advisable for other ‘idiopathic’ autoimmune diseases, 
namely autoimmune hepatitis, poly-dermatomyositis, and panarteritis nodosa, which 
although rarely may develop in the context of chronic HCV infection (1, 6, 9). Overall, first-line 
clinical work-up of HCV-positive patients may evidence signs/symptoms suggestive of the 
above diseases (Tab. 1). In particular, dyspnea and chest x-ray alterations may reveal an 
underlying interstitial lung involvement; while, myalgias, proximal muscle weakness, and/or 
increased creatine phosphokinase serum levels are highly indicative for myositic process (Tab. 
1). Conversely, patients affected by one of the above autoimmune disorders should be 
routinely evaluated for the presence of potential infectious triggering factors, including HCV 
infection (1, 6, 9, 129). These diseases are generally classified as ‘idiopathic’ conditions; they 
often represent clinical syndromes encompassing different phenotypes possibly correlated to 
different etiological factors (1, 9, 26, 28, 124, 125). Thus, the proposed pathogenetic link 
between a definite disease and HCV infection cannot be excluded a priori; the virus could play 
a pathogenetic role in a small disease subset or sporadically in individual patients at all.                                                               
Finally, a coincidental association between HCV and diseases is also possible considering the 
large diffusion of HCV infection in the general population; in any cases, the presence of simple 
comorbidity need to be always verified due to the additional implications of HCV infection in 
the whole patient management. 
 
 
1.3.3. Monitoring of HCV-infected patients 
Patients with apparently isolated HCV infection are commonly referred to tertiary specialized 
centers according to prevalent clinical manifestations. However, they should undergo to 
comprehensive clinical evaluation of possible hepatic and/or extrahepatic disorders at 
baseline and at regular time intervals during the follow-up. Tab. 1 reports the first line clinical 
work-up of HCV-infected patients that in the large majority of cases may be able to evidence 
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overt HCV-EHDs or to suggest the subclinical presence of such complications. Moreover, long-
term clinical monitoring of patients with chronic HCV infection may be decisive for early 
diagnosis of different HCV-EHDs and opportune therapeutical decisions. The careful follow-up 
and timely treatment of HCV-EHDs may affect the patients’ quality of life and prognosis, 
mainly in patients with more severe visceral organ damages and/or malignancies, mainly HCC 
and B-NHL.  
 
 
 
1.4. Discussion  
The large diffusion of HCV infection in the general population and its frequent hepatic and 
extrahepatic manifestations are a serious medical problem that involves transversally 
different medical subspecialties (1,2, 6, 11, 109). The HCV syndrome is an important model of 
chronic multisystem disease needing very often a long-term multidisciplinary management (1-
6). The necessarily holistic approach to these patients represents a great challenge for the 
clinicians because of the variety and unpredictability of HCV-EHDs. HCV-infected individuals 
are often referred to different tertiary centers according to the presenting/prevalent 
symptom(s) with the potential risk to underestimate the remaining clinical manifestations. 
As regards the diagnostic aspects, previously published studies generally analyzed a single 
manifestation at once in the variegated field of HCV-EHDs (1, 2). The present work represents 
the first attempt to draw comprehensive diagnostic guidelines for HCV-infected individuals 
encompassing the entire spectrum of HCV-EHDs, based on the specific expertise of different 
co-authors. Considering the heterogeneity of HCV syndrome and in particular of HCV-EHDs, 
the preparation of diagnostic guidelines resulted particularly difficult. They should be 
sufficiently inclusive and thorough with respect to various symptoms that may complicate the 
natural course of HCV infection, but in the same time easily manageable in the clinical practice 
by different specialists dealing with HCV-infected patients. The patient’s assessment at the 
first referral and during the follow-up should be based on the routinely adoption of first-line 
core set of diagnostic procedures, possibly integrated by deeper clinical investigations 
focusing on specific clinical manifestations. There was a broad consensus among ISG-EHCV 
members on item selection of baseline clinical evaluation; while for single HCV-EHDs, i.e. 
rheumatic, renal, hematological, and endocrine manifestations, targeted second line 
diagnostic procedures were proposed by the expert team. Moreover, when available 
classification/diagnostic criteria for single HCV-EHDs such as MCs were properly taken into 
account (17-23). 
THe HCV lymphotropism along with its striking association with MCs were firstly 
demonstrated in the early nineties soon after the HCV discovery (12, 13, 130, 131). These 
important findings prompted an increasing number of studies on different autoimmune-
lymphoproliferative HCV-EHDs (1-6). Apart from hepatic manifestations, a significant 
percentage of HCV-infected individuals may remain totally asymptomatic for years or the 
entire life. While the presence of some immunological alterations as serum rheumatoid factor 
and/or cryoglobulinemia may be occasionally found (1-7). In particular, circulating 
cryoglobulins may be detected in almost half of HCV-infected patients but without any clinical 
significance, while overt MCs may develop in less than 5% of cryoglobulinemic patients (1-6). 
Some individuals with serum antinuclear antibodies, chronic hepatitis, and one or more mild 
extrahepatic manifestations such as arthralgias/arthritis, sicca syndrome, and/or thyroiditis, 
may mimic autoimmune hepatitis; in these cases the differential diagnosis is quite feasible by 
means of current classification criteria (1-6, 9). Other overlapping conditions may regard HCV-
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infected patients with autoimmune features mimicking classical rheumatic diseases, mainly 
RA and pSS (1-6, 9, 35). In these instances, it is necessary to correctly differentiate patients 
with true ‘primary’ autoimmune diseases and concomitant HCV infection from patients with 
HCV-EHDs (1, 2, 6, 28, 35). Actually, the diagnosis of HCV-related MCs may be controversial in 
some patients because of the presence of one or more symptoms distinctive of other well-
definite autoimmune disorders (9). MCs may be correctly classified following the criteria 
elaborated by international study group proposed by GISC (Italian Study Group on 
Cryoglobulinemia) (17, 18) in the majority of cases; while in some patients it is very difficult to 
distinguish between true HCV-related MCs and other well-known conditions, particularly the 
pSS (1, 2, 6, 28). For these patients the term of ‘overlapping syndrome’ may be rather 
appropriate, mainly in consideration of the concomitant impact of HCV infection per se and 
when present of cryoglobulinemic vasculitis on the worse patients’ outcome  (1,9).                                                                                                                                        
The spectrum of HCV-EHDs is extremely heterogeneous; it includes immune-mediated, organ- 
and non-organ specific disorders as well as neoplastic manifestations (1-6, 44). The possible 
multistep contribution of different pathogenetic cofactors, genetic and environmental, may 
be decisive for the appearance of novel, specific clinical phenotypes; these latter can be 
observed at any time during the natural history of HCV infection, variably combined in 
individual patients (1, 9). Some harmful, life-threatening complications may appear abruptly; 
thus, careful clinical monitoring of HCV-infected patients is crucial for early diagnosis and 
treatment of these unpredictable manifestations. It is supposable that recently available 
direct-acting antiviral treatments leading to HCV eradication in a very high percentage of 
patients  (132, 133) may affect in the near future the natural history of HCV infection, and 
consequently the overall prevalence and outcome of hepatic and HCV-EHDs. Considering the 
extrahepatic manifestations, some preliminary studies regarding small patients series 
demonstrated a marked improvement or disappearance of some symptoms, particularly MCs 
or lymphomatous complications (1-6). However, it is supposable that profound HCV-driven 
immune-system alterations may result totally or at least in part irreversible in some patients, 
mainly in those with long-lasting viral infection. Thus, current antiviral treatments might lead 
to novel, unforeseeable scenarios. Future clinical trials focusing on patients with sustained 
virological response might elucidate the above questions; these studies may be decisive in 
order to quantify the actual percentage of remission of different HCV-EHDs, as well as to 
identify possible predictive factors of different disease outcomes.                                                                                                                               
In conclusion, a multidisciplinary approach to HCV-infected patients is greatly advisable since 
the first patient’s evaluation; comprehensive clinical assessment following standardized 
diagnostic guidelines is critical for the whole patients’ management and therapeutic strategies, 
as well as for pathogenetic studies focusing on homogeneous clinical subsets. 
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Take-home messages  
(for Autoimmunity Reviews) 
 
 Hepatitis C virus (HCV) infection is responsible for both hepatic and extra-hepatic disorders 
(HCV-EHDs) 
 Due to clinical heterogeneity of HCV-EHDs, patients may be referred to different specialists 
 Comprehensive diagnostic guidelines are necessary for a whole patient’s assessment at the 
first referral and during the follow-up 
 The International Study Group of Extrahepatic Manifestations Related to HCV Infection 
elaborated diagnostic guidelines of HCV-EHDs 
 All HCV-infected patients should undergo first-line diagnostic procedures able to identify 
one or more HCV-EHDs 
 Patients with suspected HCV-EHDs will be deeper investigated by means of second-line, 
targeted investigations 
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Legend to the Figures 
Fig. 1. Various HCV-EHDs can be classified according to the strength of the association 
evaluated on the basis of epidemiological, clinico-pathological, virological, and 
laboratory investigations. This subsetting is quite definite with regards the first 2 groups, 
while other associations are waiting for a right qualification. 
1: HCV represents the main etiological agent as concordantly demonstrated by all the 
above investigations;  
 
2: the association between HCV and disease is demonstrated in a significant proportion 
of patients compared to general population (often with heterogeneous geographical 
distribution), its potential role is supported by in depth clinico-pathogenetic studies; 
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3: a role of HCV infection has been suggested by cohort studies; a possible causative 
role may be limited to a small number of patients and/or possibly more relevant in 
specific geographical areas; 
 
4: a number of anecdotal observations suggested a possible role of HCV; further 
investigations are required. 
 
B-cell NHL:  B-cell non-Hodgkin’s lymphomas; PCT: porphyria cutanea tarda; SS: typical features of 
Sjögren’s syndrome; PM/DM: polymyositis / dermatomyositis: PAN: panarteritis nodosa 
 
 
Fig. 2. The Network of HCV-related Disorders 
The figure is a schematic representation of the network of HCV-related disorders, which 
encompasses both hepatic and extrahepatic diseases (HCV-EHDs).  
Liver involvement represents the most common clinical manifestation of chronic HCV 
infection, while HCV-EHDs may develop in a minority of patients. 
HCV-EHDs may appear either as organ-specific disorders, i.e. arthritis, neuropathy, 
glomerulonephritis, etc.) or as systemic autoimmune disorder such as mixed 
cryoglobulinemia syndrome (MCs). Isolated and totally asymptomatic serum 
cryoglobulins are generally detectable in over 50% of HCV infected individuals, while 
classical MCs can be diagnosed in a small percentage of patients on the basis of both 
serological (circulating mixed cryoglobulins) and typical clinic-pathological features (see 
text).  
In the clinical practice we can observe a variable combination of hepatic and HCV-EHDs 
among HCV-infected patients, as well as in the same patient during the long-term 
follow-up. The most harmful complications of chronic HCV infection may appear 
abruptly (sensory-motor peripheral neuropathy, glomerulonephritis, widespread 
vasculitis, etc.) or more often as late manifestations (malignancies), alone or in the 
setting of MCs. 
 
B-NHL:  B-cell non-Hodgkin’s lymphomas; HCC: hepatocellular carcinoma       
 
 
 
 
 
 
Fig. 3. Clinical assessment of HCV-infected individuals 
The figure shows the diagnostic steps for a correct diagnostic assessment of HCV-related 
extrahepatic disorders (HCV-EHDs). At the first assessment all patients with chronic HCV 
infection should be investigated for possible hepatic and/or HCV-EHDs through a first-
line investigations in order to detect signs and symptoms, anamnestic/present, by 
means of standardized questionnaire, physical examination, and a core set of 
laboratory/instrumental procedures (see also Tab. 1). Individuals with symptoms 
suggestive of possible HCV-EHDs will be deeply evaluated by means of targeted 
investigations that may define different HCV-EHDs (see text). In all cases, the presence 
of underlying disorders potentially responsible for HCV-EHDs should be excluded, mainly 
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other infectious agents (HBV, HIV, etc.) or neoplastic diseases. 
 
HCC: hepatocellular carcinoma; MCs: mixed cryoglobulienmia syndrome; SS: sicca syndrome (in few cases 
typical features of Sjögren’s syndrome); PCT: porphyria cutanea tarda; B-NHL: B-cell non-Hodgkin’s 
lymphomas; °Others: see Fig. 1. 
 
 
Fig. 4. General clinical assessment of HCV-EHDs 
The figure shows in detail the diagnostic guidelines with first- and second-line 
investigations to detect single HCV-related extrahepatic disorders (HCV-EHDs) (see also 
text, Tab. 1, and Fig. 3). 
 
FNA: fine-needle aspiration of thyroid nodules  
Doppler-US: transcranial color-Doppler ultrasonography; MRI: magnetic resonance imaging CT: computed tomography 
angiography; PET: positron emission tomography; RF: rheumatoid factor; anti-CCP: anti-cyclic citrullinated peptide 
antibodies; ANA: anti-nuclear antibodies; ENA: anti-nuclear extractable antigen antibodies; URO-D: uroporphyrinogen 
decarboxylase; GN: glomerulonephritis (diffuse membranoproliferative glomerulonephritis in about 80 % of case).  
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Tab. 1.  HCV-infected individuals: detection of extra-hepatic manifestations 
                              
                  Signs and symptoms   First line 
                  (anamnestic/present)  laboratory investigations 
       
Constitutional Weakness  Liver function tests 
  Fever  Routine blood chemistry 
  Weight loss   Virological tests 
  Myalgias, fibromyalgia  ESR, CRP 
     RF 
Skin inv. Orthostatic purpura  Cryoglobulinemia 
  Necrotizing vasculitis  Complement C3/C4 
  Skin ulcers  Serum immunofixation  
  bullae/hyperpigmentation/   ANA, anti-ENA 
  erosions at sun-exposed areas  TSH 
     Urinalysis 
Articular inv. Arthralgias    
  Arthritis  Abdominal/thyroid ultrasonography 
     EKG 
Salivary gland inv. sicca syndrome  Chest x-ray 
       
Renal inv. Edema    
       
Vascular inv.  Hypertentension    
  Raynaud’s phenomenon    
  Hyperviscosity syndrome    
       
Heart/lung inv.  Dyspnea, edema, hemoptoe    
  pleural/pericardial effusion    
  claudication, heart failure    
       
Neurological inv. Peripheral neuropathy    
  Cranial nerve involvement    
  CNS involvement*    
       
Hematolocical inv. Adenopathy    
  
Splenomegaly 
Cytopenias 
Lymphocytosis 
Monoclonal component 
Systemic symptoms  
 
  
       
Endocrine inv. hypothyroidism    
  Diabetes type 2    
  Erectile dysfunction    
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ESR: erythrocyte sedimentation rate; CRP: C reactive protein; RF: rheumatoid factor; ANA: anti-nuclear antibodies; 
anti-ENA: antibodies anti-extractable nuclear antigens; TSH: thyroid-stimulating hormone; EKG: electrocardiogram 
 
 
 
 
 
 
 
 
 
 
Tab. 2. Differential diagnosis between some HCV-EHDs and idiopathic rheumatic diseases 
        
 Mixed cryogl.  Sicca syndrome pSjögren's   Arthritis Rheumatoid 
 HCV+   HCV+  syndrome   HCV+ arthritis 
Symptoms        
Purpura  +++   +/-  +/-   +/-  +/- 
Weakness  +++   +  +   +  +/- 
Arthralgias +++   +/-  +/-   +++  +++ 
Oligoarthritis   +   +  +   +  + 
Polyarthritis   +/-   +/-  +   +  +++ 
Erosive arthritis  -   -  +/-   +/-  +++ 
sicca syndrome  +   +++  +++   +/-  +/- 
Renal inv.  ++   +/-  +   +/-  +/- 
Peripheral neuropathy  ++   +/-  +   +/-  +/- 
B-NHL  +   +/-  +   +/-  +/- 
        
Laboratory alterations        
Mixed cryoglobulins +++   +/-  +   +/-  +/- 
Low complement C4  +++   +/-  -   +/-  - 
RF +++   +/-  +++   +/-  ++ 
anti-CCP Ab  -   -  -   -  ++ 
ANA  +/-   +/-  +++   +/-  +/- 
anti-SSA/SSB Ab  +/-   +/-  +++   -  - 
Salivary gland biopsy  +/-    +/-  +++   +/-  +/- 
                
Colored areas highlight the parameters useful for differential diagnosis.  
B-NHL: B-cell non-Hodgkin’s lymphomas; RF: rheumatoid factor; anti-CCP: anti-cyclic citrullinated peptide antibodies; 
ANA: anti-nuclear antibodies 
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